Oncology Institute, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Mohit Kaushal, a Director of Oncology Institute, Inc., received 33,133 shares of common stock on July 27, 2026.
NASDAQ
Anne Mcgeorge, a Director of Oncology Institute, Inc., received 41,165 shares of common stock on July 27, 2026.
NASDAQ
Mark L Pacala, a Director of Oncology Institute, Inc., received 30,120 shares of common stock on July 27, 2026.
NASDAQ
Mark Stolper, a Director of Oncology Institute, Inc., received 31,124 shares of common stock on July 27, 2026.
NASDAQ
Kimberly Jo Tzoumakas, a Director of Oncology Institute, Inc., received 29,116 shares of common stock on July 27, 2026.
NASDAQ
Brad Hively, a Director of Oncology Institute, Inc., received 27,108 shares of common stock on July 27, 2026.
NASDAQ
Karen Marie Johnson, a Director of Oncology Institute, Inc., received 31,124 shares of common stock on July 27, 2026.
NASDAQ
Jorey Chernett, a 10% owner of Oncology Institute, Inc., purchased 18,000 shares of common stock on July 21, 2026 for $5.27 per share.
NASDAQ
Yale Podnos, Chief Medical Officer of Oncology Institute, Inc., sold 23,452 shares of common stock on July 14, 2026.
NASDAQ
Jorey Chernett, a 10% owner of Oncology Institute, Inc., purchased 15,000 shares of common stock on July 10, 2026 for $5.85 per share.
NASDAQ
Kimberly Tzoumakas, a Director at Oncology Institute, Inc., acquired 17,185 shares of common stock on July 7, 2026, through a vested RSU award.
NASDAQ
Director Mark Stolper of Oncology Institute, Inc. reported the acquisition of 25,833 shares of common stock through a fully vested RSU award.
NASDAQ
Director Jorey Chernett acquired 18,000 shares of common stock in Oncology Institute, Inc. for approximately $5.02 per share.
NASDAQ
Yale Podnos, Chief Medical Officer of The Oncology Institute, Inc., sold 23,451 shares of common stock via a 10b5-1 plan.
NASDAQ
Reporting person Jorey Chernett acquired 12,000 shares of The Oncology Institute, Inc. common stock at $4.75 per share.
NASDAQ
Chief Medical Officer Yale Podnos sold 1,805 shares of The Oncology Institute to satisfy tax obligations related to RSU vesting.
NASDAQ
The Oncology Institute CEO Daniel Virnich disposed of 23,058 shares to cover tax liabilities related to RSU vesting.
NASDAQ
CFO Robert Carter sold 1,604 shares of The Oncology Institute, Inc. to satisfy tax obligations related to RSU vesting.
NASDAQ
Jorey Chernett, a Director and 10% owner of Oncology Institute, Inc., reported the purchase of 38,500 shares of common stock.
NASDAQ
Director Jorey Chernett acquired 30,000 shares of Oncology Institute, Inc. common stock for approximately $4.09 per share.
NASDAQ
Oncology Institute, Inc. announced that Kristin England has ceased to be an officer of the company for Section 16 reporting purposes effective April 21, 2026.
NASDAQ
Jeffrey Langsam has been removed from the list of Section 16 officers at Oncology Institute, Inc. following a board decision.
NASDAQ
Director Mohit Kaushal sold 95,719 shares of The Oncology Institute, Inc. (TOI) via a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Jorey Chernett, a Director at Oncology Institute, Inc., acquired 20,000 shares of common stock.
NASDAQ
Jeffrey Langsam, Chief Clinical Officer of The Oncology Institute, Inc., was granted 70,270 shares of common stock as Restricted Stock Units.
NASDAQ
Kristin England, Chief Administrative Officer of Oncology Institute, Inc., acquired 55,743 shares of common stock through a Restricted Stock Unit (RSU) award.
NASDAQ
The Oncology Institute's Chief Medical Officer, Yale Podnos, reported the vesting of 66,446 restricted stock units and a subsequent sale of 16,173 shares to cover tax obligations.
NASDAQ
The Oncology Institute's CFO, Robert Ross Carter, reported the acquisition of 202,914 shares through an RSU award and the sale of 20,320 shares to cover tax liabilities.
NASDAQ
The Oncology Institute CEO Daniel Virnich reported the acquisition of 670,608 shares via RSU awards and the sale of 98,534 shares to cover tax liabilities.
NASDAQ
Oncology Institute (TOI) 10% owner Jorey Chernett reported an open-market purchase of 27,429 shares at $2.96, increasing direct holdings to 10,479,358 shares.